2022 World Conference on Lung Cancer (ePosters)-EP02.04-009. Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC

EP02.04-009. Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC

Pdf Summary

A study conducted at the Princess Margaret Cancer Centre in Toronto, Canada, examined the real-world outcomes of adjuvant therapies in patients with early-stage non-small cell lung cancer (NSCLC) who did not have EGFR mutations or ALK rearrangements. The researchers analyzed the effects of adjuvant chemotherapy, post-operative radiation therapy, and adjuvant chemoradiation on overall survival.<br /><br />The study included patients with resected stage IB-IIIA NSCLC and excluded those who received neoadjuvant therapy or had specific genetic mutations. Survival analyses were conducted using Cox proportional hazards models adjusted for age, sex, stage at diagnosis, and smoking history.<br /><br />The results showed that less than 50% of patients with resected stage IB-IIIA NSCLC received adjuvant chemotherapy. However, those who did receive adjuvant chemotherapy demonstrated a benefit in overall survival, with a hazard ratio similar to the benefits reported in the LACE consortium. On the other hand, post-operative radiation therapy, which is a surrogate for more advanced tumors, was associated with worse outcomes.<br /><br />The study also provided information on the characteristics of the patients included in the analysis. The median age was 68.8 years, and the majority of patients were male (51.3%) and ex-smokers (51.3%). The distribution of tumor stage showed that 43.1% of patients had stage IIB NSCLC, followed by stage IB (25%), stage IIA (19.7%), and stage IIIA (18.1%). The most common histologic type of tumor was adenocarcinoma (58.9%).<br /><br />In conclusion, this study found that adjuvant chemotherapy provided a survival benefit for patients with early-stage NSCLC, while post-operative radiation therapy was associated with worse outcomes. These findings highlight the importance of considering individual patient characteristics and tumor biology when selecting the appropriate adjuvant therapy for early-stage NSCLC.

Asset Subtitle

Tedi Hoxha

Meta Tag

Speaker Tedi Hoxha

Topic Early Stage Non-small Cell Lung Cancer - Systemic Therapy

Keywords

Princess Margaret Cancer Centre

adjuvant therapies

non-small cell lung cancer

NSCLC

adjuvant chemotherapy

post-operative radiation therapy

overall survival

resected stage IB-IIIA NSCLC

tumor stage

adenocarcinoma